The Asia Pacific Pruritus Therapeutics Market should witness market growth of 5.1% CAGR during the forecast period (2023-2030).
The market's primary drivers are leading market firms that make significant R&D investments to produce cutting-edge pruritus cures. Additionally, investments are made to advance existing pruritus treatments. A strong product pipeline and the launch of new medications are top priorities for the major rivals. Moreover, over-the-counter topical medications are in considerable demand due to their low cost, similar effectiveness, and ease of availability. As a result, people are using over-the-counter medications more frequently. These factors create a favorable atmosphere for boosting pruritus product sales as well as for the expansion of the market. In several instances, the cause of the disease is unknown.
Launching novel products to treat the diseases and the high prevalence of dermatological conditions such as atopic dermatitis, urticaria, cutaneous T-cell, psoriasis, and allergic contact dermatitis are expected to fuel market expansion. Pruritus brachialis, pruritus ani, pruritus uremic, nocturnal, and senile pruritus are forms of pruritus that can affect humans and may affect a particular area of the body or the entire body. If the itching is not severe, it can be prevented by keeping the skin clean, moisturized, and free of noticed allergens by avoiding scratching. Pruritus therapeutics are drugs that are used to cure itching.
Over the past few decades, the frequency of atopic dermatitis has increased in Asian nations, specifically worldwide. This increased frequency in Asian nations has been linked to several developments, including rapid urbanization, a shift toward more Westernized lifestyles, and higher living and educational standards. It is crucial to understand the rising disease demand in Asian nations and their variations in terms of epidemiology, diagnostic standards, management, quality of life, and financial burden. The point prevalence of A.D. was 2.42% after normalizing (2.39% in men and 2.46% in women). According to estimates, the market expansion in the APAC region will be supported by the increased prevalence of A.D. in the region.
The China market dominated the Asia Pacific Pruritus Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $786.8 million by 2030. The Japan market is estimated to witness a CAGR of 4.4% during (2023-2030). Additionally, India's market would showcase a CAGR of 5.7% during (2023-2030).
Based on Disease Type, the market is segmented into Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria and Others. Based on Product, the market is segmented into Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Novartis AG, Pfizer, Inc., Sanofi S.A., Astellas Pharma, Inc., Cara Therapeutics, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceuticals Industries Ltd., Amgen, Inc., and AbbVie, Inc.
The market's primary drivers are leading market firms that make significant R&D investments to produce cutting-edge pruritus cures. Additionally, investments are made to advance existing pruritus treatments. A strong product pipeline and the launch of new medications are top priorities for the major rivals. Moreover, over-the-counter topical medications are in considerable demand due to their low cost, similar effectiveness, and ease of availability. As a result, people are using over-the-counter medications more frequently. These factors create a favorable atmosphere for boosting pruritus product sales as well as for the expansion of the market. In several instances, the cause of the disease is unknown.
Launching novel products to treat the diseases and the high prevalence of dermatological conditions such as atopic dermatitis, urticaria, cutaneous T-cell, psoriasis, and allergic contact dermatitis are expected to fuel market expansion. Pruritus brachialis, pruritus ani, pruritus uremic, nocturnal, and senile pruritus are forms of pruritus that can affect humans and may affect a particular area of the body or the entire body. If the itching is not severe, it can be prevented by keeping the skin clean, moisturized, and free of noticed allergens by avoiding scratching. Pruritus therapeutics are drugs that are used to cure itching.
Over the past few decades, the frequency of atopic dermatitis has increased in Asian nations, specifically worldwide. This increased frequency in Asian nations has been linked to several developments, including rapid urbanization, a shift toward more Westernized lifestyles, and higher living and educational standards. It is crucial to understand the rising disease demand in Asian nations and their variations in terms of epidemiology, diagnostic standards, management, quality of life, and financial burden. The point prevalence of A.D. was 2.42% after normalizing (2.39% in men and 2.46% in women). According to estimates, the market expansion in the APAC region will be supported by the increased prevalence of A.D. in the region.
The China market dominated the Asia Pacific Pruritus Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $786.8 million by 2030. The Japan market is estimated to witness a CAGR of 4.4% during (2023-2030). Additionally, India's market would showcase a CAGR of 5.7% during (2023-2030).
Based on Disease Type, the market is segmented into Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria and Others. Based on Product, the market is segmented into Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Novartis AG, Pfizer, Inc., Sanofi S.A., Astellas Pharma, Inc., Cara Therapeutics, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceuticals Industries Ltd., Amgen, Inc., and AbbVie, Inc.
Scope of the Study
By Disease Type
- Atopic Dermatitis
- Allergic Contact Dermatitis
- Urticaria
- Others
By Product
- Corticosteroids
- Antihistamines
- Local Anesthetics
- Counterirritants
- Immunosuppressant
- Calcineurin Inhibitors
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Bristol Myers Squibb Company
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Astellas Pharma, Inc.
- Cara Therapeutics, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- AbbVie, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Pruritus Therapeutics Market by Disease Type
Chapter 5. Asia Pacific Pruritus Therapeutics Market by Product
Chapter 6. Asia Pacific Pruritus Therapeutics Market by Distribution Channel
Chapter 7. Asia Pacific Pruritus Therapeutics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bristol Myers Squibb Company
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Astellas Pharma, Inc.
- Cara Therapeutics, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- AbbVie, Inc.
Methodology
LOADING...
